Levicept Ltd revealed Phase II clinical trial data for LEVI-04, a novel osteoarthritis treatment, at the EULAR 2026 conference. The data suggest LEVI-04 not only relieves pain but may also modify the disease by reducing bone marrow lesions linked to osteoarthritis severity. LEVI-04 showed improvements in pain and function comparable or superior to NSAIDs, with a differentiated safety profile from other treatments. Further presentations will detail its unique mechanism and clinical benefits, supporting its potential as a first-in-class therapy for osteoarthritis.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
